Author:
Ahmad Umar,Raihan Juraimi,Yong Yoke Keong,Eshak Zolkapli,Othman Fauziah,Ideris Aini
Abstract
AbstractBackgroundDifferent strains of Newcastle disease virus (NDV) worldwide proved to have tumouricidal activity in several types of cancer cells. However, the possible anti-cancer activity of Malaysian NDV AF2240 strain and its mechanism of action remains unknown. The ability of cytokine-related apoptosis-inducing NDV AF2240 to treat breast cancer was investigated in the current study.MethodsA total of 90 mice were used and divided into 15 groups, each group comprising of 6 mice. Tumour, body weight and mortality of the mice were determined throughout the experiment, to observe the effect of NDV and NDV+Tamoxifen treatments on the mice. In addition, the toxic effect of the treatments was determined through liver function test. In order to elucidate the involvement of cytokine production induced by NDV, a total of six cytokines, i.e. IL-6, IFN-γ, MCP-1, IL-10, IL12p70 and TNF-α were measured using cytometric bead array assay (plasma) and enzyme-linked immunosorbent spot (isolated splenocytes).ResultsThe results demonstrated that 4T1 breast cancer cells in allotransplanted mice treated with AF2240 showed a noticeable inhibition in tumour growth and induce apoptotic-related cytokines.ConclusionNDV AF2240 suppression of breast tumour growth is associated with induction of apoptotic-related cytokines.
Publisher
Cold Spring Harbor Laboratory
Reference76 articles.
1. Omar ZA , Tamin NSI : National Cancer Registry Report 2007. Malaysia Cancer Statistics-Data and Figure, Kuala Lumpur: National Cancer Registry, Ministry of Health Malaysia 2011, 89.
2. National Cancer Registry Report. Malaysia Cancer Statistics – Data and Figure 2007.
3. Epidemiology of breast cancer in Malaysia;Asian Pac J Cancer Prev,2006
4. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer;Br J Pharmacol,1993
5. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer